Sponsor: Gilead Sciences, Inc.
Sponsor Study ID: ASCENT-05 / GS-US-595-6184
Study Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
CTO #: 103898
NCT Number: NCT05633654
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To compare invasive disease-free survival (iDFS) between SG and pembrolizumab versus treatment of physician s choice (TPC)